<DOC>
	<DOCNO>NCT00142974</DOCNO>
	<brief_summary>This study do evaluate safety , tolerability satisfactory relief tegaserod dyspeptic symptom diabetic patient symptom diabetic gastropathy .</brief_summary>
	<brief_title>Assessment Effect Tegaserod ( 2 mg Tid 6 mg Tid ) Dyspeptic Symptoms Diabetic Patients With Symptoms Diabetic Gastropathy</brief_title>
	<detailed_description />
	<mesh_term>Stomach Diseases</mesh_term>
	<mesh_term>Tegaserod</mesh_term>
	<criteria>History Type 1 insulinrequiring Type 2 diabetes least 3 year GI symptoms least 2 month enter study Very high body weight Significant diarrhea Ulcers Symptom severity score collect via diary Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Diabetes , tegaserod , gastropathy</keyword>
</DOC>